Comparative Pharmacology
Head-to-head clinical analysis: CLINIMIX E 4 25 20 SULFITE FREE W ELECT IN DEXTROSE 20 W CALCIUM IN PLASTIC CONTAINER versus EPANOVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINIMIX E 4 25 20 SULFITE FREE W ELECT IN DEXTROSE 20 W CALCIUM IN PLASTIC CONTAINER versus EPANOVA.
CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER vs EPANOVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Intravenous amino acids and dextrose provide essential nitrogen and calories for protein synthesis and energy metabolism. Electrolytes maintain osmotic balance and cellular function. Calcium is critical for neuromuscular transmission and bone health.
Omega-3 fatty acids (EPA and DHA) reduce hepatic very low-density lipoprotein (VLDL) synthesis and increase triglyceride clearance from circulating VLDL particles through activation of lipoprotein lipase.
Intravenous infusion: Adult dose is based on protein and caloric requirements. Typical dose: 1-2 L/day of this 4.25% amino acid, 20% dextrose solution, providing approximately 4.25 g amino acid/100 mL and 680 kcal/L. Infusion rate should be adjusted to avoid hyperglycemia, usually starting at 25-50 mL/hr and increasing gradually.
4 g orally once daily as 4 capsules of 1 g each with food.
None Documented
None Documented
Not applicable as a single entity; components have distinct half-lives: dextrose ~1.5-2 hours (glucose); amino acids ~5-10 minutes; electrolytes vary (e.g., calcium ~2-3 hours). Clinical context: continuous infusion achieves steady state.
Terminal elimination half-life approximately 89 hours (range 59–144 hr); allows weekly intramuscular dosing.
The amino acids and electrolytes are metabolized or utilized; dextrose is oxidized to CO2 and water. Renal excretion of nitrogen is ~60-80% as urea, with minor losses in feces (5-10%) and skin (2-5%). Electrolytes are excreted primarily renally.
Primarily hepatic metabolism via omega-oxidation and subsequent conjugation; renal excretion of metabolites: ~15% unchanged in urine; biliary/fecal elimination accounts for ~85% as metabolites.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution